These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 31082394

  • 1. Prevalence and predictors of initiation of intrauterine devices and subdermal implants immediately after surgical abortion.
    Roe AH, Fortin J, Janiak E, Maurer R, Goldberg AB.
    Contraception; 2019 Aug; 100(2):89-95. PubMed ID: 31082394
    [Abstract] [Full Text] [Related]

  • 2. Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond.
    Rose SB, Garrett SM, Stanley J.
    Contraception; 2015 Jul; 92(1):17-25. PubMed ID: 25818594
    [Abstract] [Full Text] [Related]

  • 3. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons.
    Saloranta TH, Gyllenberg FK, But A, Gissler M, Laine MK, Heikinheimo O.
    Am J Obstet Gynecol; 2020 Dec; 223(6):886.e1-886.e17. PubMed ID: 32562657
    [Abstract] [Full Text] [Related]

  • 4. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE, Upadhyay UD, Sokoloff A, Harper CC, Diedrich JT, Drey EA.
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [Abstract] [Full Text] [Related]

  • 5. Postabortion Initiation of Long-Acting Reversible Contraception by Adolescent and Nulliparous Women in New Zealand.
    Rose SB, Garrett SM.
    J Adolesc Health; 2016 Feb; 58(2):160-6. PubMed ID: 26603946
    [Abstract] [Full Text] [Related]

  • 6. Changes in uptake and cost of long-acting reversible contraceptive devices following the introduction of a new low-cost levonorgestrel IUD in Utah's Title X clinics: a retrospective review.
    Roth LP, Sanders JN, Simmons RG, Bullock H, Jacobson E, Turok DK.
    Contraception; 2018 Jul; 98(1):63-68. PubMed ID: 29574095
    [Abstract] [Full Text] [Related]

  • 7. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
    Bosco-Lévy P, Gouverneur A, Langlade C, Miremont G, Pariente A.
    Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg versus other long-acting reversible contraceptives for contraception in Spain.
    Conde JCQ, Parra Ribes I, Perelló-Capo J, Lobo Abascal P, García IC, Andeyro García M, Gutiérrez Alés J, Herrero Conde M, Rius Tarruella J, Espinós Lafuente B.
    Eur J Contracept Reprod Health Care; 2024 Oct; 29(5):224-232. PubMed ID: 38989683
    [Abstract] [Full Text] [Related]

  • 9. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
    Bahamondes L, Bottura BF, Bahamondes MV, Gonçalves MP, Correia VM, Espejo-Arce X, Sousa MH, Monteiro I, Fernandes A.
    Hum Reprod; 2014 Oct 10; 29(10):2163-70. PubMed ID: 25085802
    [Abstract] [Full Text] [Related]

  • 10. Preference for and efficacy of oral levonorgestrel for emergency contraception with concomitant placement of a levonorgestrel IUD: a prospective cohort study.
    Turok DK, Sanders JN, Thompson IS, Royer PA, Eggebroten J, Gawron LM.
    Contraception; 2016 Jun 10; 93(6):526-32. PubMed ID: 26944863
    [Abstract] [Full Text] [Related]

  • 11. Changes in body composition in women using long-acting reversible contraception.
    Silva Dos Santos PN, Madden T, Omvig K, Peipert JF.
    Contraception; 2017 Apr 10; 95(4):382-389. PubMed ID: 28041992
    [Abstract] [Full Text] [Related]

  • 12. Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database.
    Agostini A, Godard C, Laurendeau C, Benmahmoud Zoubir A, Lafuma A, Lévy-Bachelot L, Gourmelen J, Linet T.
    Eur J Contracept Reprod Health Care; 2018 Dec 10; 23(6):421-426. PubMed ID: 30499732
    [Abstract] [Full Text] [Related]

  • 13. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J, Heikinheimo O, Lähteenmäki P, Suhonen S.
    Hum Reprod; 2015 Jul 10; 30(7):1580-8. PubMed ID: 25990577
    [Abstract] [Full Text] [Related]

  • 14. Long-Acting Reversible Contraceptive Placement Among Active-Duty U.S. Army Servicewomen.
    Erickson AK, Nelson DA, Shaw JG, Loftus PD, Kurina LM, Shaw KA.
    Obstet Gynecol; 2017 May 10; 129(5):800-809. PubMed ID: 28383371
    [Abstract] [Full Text] [Related]

  • 15. Association Between Women's Use of Long-Acting Reversible Contraception and Declining Abortion Rates in New Zealand.
    Whitley CE, Rose SB, Sim D, Cook H.
    J Womens Health (Larchmt); 2020 Jan 10; 29(1):21-28. PubMed ID: 31600111
    [Abstract] [Full Text] [Related]

  • 16. Long-acting reversible contraception immediately after medical abortion: systematic review with meta-analyses.
    Schmidt-Hansen M, Hawkins JE, Lord J, Williams K, Lohr PA, Hasler E, Cameron S.
    Hum Reprod Update; 2020 Feb 28; 26(2):141-160. PubMed ID: 32096862
    [Abstract] [Full Text] [Related]

  • 17. [Long-acting reversible contraception methods in women under 26 years of age].
    Frutos-Balibrea I, Sánchez-Núñez MI, Pedrero-Pérez EJ, Haro-León A, Benítez-Robredo MT.
    Semergen; 2021 Oct 28; 47(7):457-464. PubMed ID: 34148782
    [Abstract] [Full Text] [Related]

  • 18. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception.
    Bilgehan F, Dilbaz B, Karadag B, Deveci CD.
    J Obstet Gynaecol Res; 2015 Sep 28; 41(9):1426-32. PubMed ID: 26180028
    [Abstract] [Full Text] [Related]

  • 19. Obstetrician-gynecologists and contraception: long-acting reversible contraception practices and education.
    Luchowski AT, Anderson BL, Power ML, Raglan GB, Espey E, Schulkin J.
    Contraception; 2014 Jun 28; 89(6):578-83. PubMed ID: 24656553
    [Abstract] [Full Text] [Related]

  • 20. Risk factors and the choice of long-acting reversible contraception following medical abortion: effect on subsequent induced abortion and unwanted pregnancy.
    Korjamo R, Heikinheimo O, Mentula M.
    Eur J Contracept Reprod Health Care; 2018 Apr 28; 23(2):89-96. PubMed ID: 29537321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.